Effect of pegylated interferon and ribavirin therapy on the QOL in the treatment of chronic hepatitis C

Not Applicable

• Conditions: chronic hepatitis C

• Registration Number: JPRN-UMIN000003988
• Lead Sponsor: Tokai University School of Medicine, Department of Internal Medicine, Division of Gastroenterology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-08-10
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients who were previously treated with pegylated interferon and ribavirin therapy. 2. Patients who are pregnant or lactating. 3. Patients who cannot use birth control until 6 months pass after the end of treatment. 4. Patients who have hypersensitivity to interferons or ribavirin. 5. Patients who have uncontrolled heart diseases. 6. Patients with abnormal hemoglobin diseases. 7. Patients with chronic renal failure. 8. Patients with severe depression. 9. Patients with severe liver diseases. 10. Patients with autoimmune disorders. 11. Patients receiving other antiviral drugs, immunomodulating drugs, or Sho-Sai-Ko-To. 12. Patients who have hypersensitivity to aspirin or NSAID. 13. Patients who have peptic ulcers. 14. Patients who have asthma induced by aspirin or NSAID. 15. Patients who received antiviral therapy within 6 months. 16. Patients who have a history of interstitial pneumonia.

Study & Design

• Study Type: Interventional
• Study Design: Not specified